Loading…
VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months
Abstract Objectives We report our institutional experience using VS38 to evaluate plasma cells by flow cytometry. Methods Flow cytometry data were reanalyzed to compare plasma cell percentages between the standard panel and VS38 panel. Natural killer (NK) and plasma cell CD38 median fluorescence int...
Saved in:
| Published in: | American journal of clinical pathology 2020-02, Vol.153 (2), p.221-228 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c452t-bb2421a954cbcdf884265d8d419cbf4486f8a1d4969020bfb8dfaf8e0bfe0fd93 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c452t-bb2421a954cbcdf884265d8d419cbf4486f8a1d4969020bfb8dfaf8e0bfe0fd93 |
| container_end_page | 228 |
| container_issue | 2 |
| container_start_page | 221 |
| container_title | American journal of clinical pathology |
| container_volume | 153 |
| creator | Courville, Elizabeth L Yohe, Sophia Shivers, Paula Linden, Michael A |
| description | Abstract
Objectives
We report our institutional experience using VS38 to evaluate plasma cells by flow cytometry.
Methods
Flow cytometry data were reanalyzed to compare plasma cell percentages between the standard panel and VS38 panel. Natural killer (NK) and plasma cell CD38 median fluorescence intensity (MFI) values were calculated.
Results
Our cohort included 63 specimens from 38 patients. Twenty-six had received daratumumab (monoclonal anti-CD38 therapy) between less than 1 month and 17 months prior. For NK and plasma cells, CD38 MFI values were suppressed for 0 to 4 months and started to increase 4 to 6 months after last exposure. There was no significant difference in clonal plasma cell percentage calculated by the VS38 and standard panels; however, identification and quantification using the VS38 panel were easier.
Conclusions
VS38 is a viable alternative to bright CD38 to identify plasma cells and particularly helpful in myeloma cases with dim CD38 and after daratumumab. Daratumumab interference with CD38 identification persists 4 to 6 months after the last exposure. |
| doi_str_mv | 10.1093/ajcp/aqz153 |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2311920763</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A645080060</galeid><oup_id>10.1093/ajcp/aqz153</oup_id><sourcerecordid>A645080060</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-bb2421a954cbcdf884265d8d419cbf4486f8a1d4969020bfb8dfaf8e0bfe0fd93</originalsourceid><addsrcrecordid>eNp9ktFqFDEUhgdR7Fq98l4CQhF02iSTySSXZbfVhRYFq70MmUzSzTKTTJMMur6L72rWqRVFJBfJCd_5OCF_UTxH8BhBXp3IrRpP5O03VFcPigXipCqbBuOHxQJCiEuOmuqgeBLjFkKEGSSPi4MK0YbnalF8__yxYmDdaZessTqCy53u_SDBUvd9BNc2bcDKDmC5ytjZ1zHoGK13QLoOfOhlvCfPfd_7L9bdgJUMMk3DNMgWXG10kOPuDbjeWLUBa5d0MDpLZvNP60onrdJeanwABCQPKLj0Lm3i0-KRkX3Uz-72w-LT-dnV8l158f7tenl6USpS41S2LSYYSV4T1arOMEYwrTvWEcRVawhh1DCJOsIphxi2pmWdkYbpfNTQdLw6LF7N3jH420nHJAYbVX6XdNpPUeAKIY5hQ6uMvvwL3fopuDydyEPUNaWQ8t_Ujey1sM74FKTaS8UpJTVkEFKYqeN_UHl1erDKO21svv-j4fXcoIKPMWgjxmAHGXYCQbEPg9iHQcxhyPSLu1GndtDdPfvr9zNwNAN-Gv9r-gFy-bt8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425566069</pqid></control><display><type>article</type><title>VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months</title><source>Oxford Journals Online</source><creator>Courville, Elizabeth L ; Yohe, Sophia ; Shivers, Paula ; Linden, Michael A</creator><creatorcontrib>Courville, Elizabeth L ; Yohe, Sophia ; Shivers, Paula ; Linden, Michael A</creatorcontrib><description>Abstract
Objectives
We report our institutional experience using VS38 to evaluate plasma cells by flow cytometry.
Methods
Flow cytometry data were reanalyzed to compare plasma cell percentages between the standard panel and VS38 panel. Natural killer (NK) and plasma cell CD38 median fluorescence intensity (MFI) values were calculated.
Results
Our cohort included 63 specimens from 38 patients. Twenty-six had received daratumumab (monoclonal anti-CD38 therapy) between less than 1 month and 17 months prior. For NK and plasma cells, CD38 MFI values were suppressed for 0 to 4 months and started to increase 4 to 6 months after last exposure. There was no significant difference in clonal plasma cell percentage calculated by the VS38 and standard panels; however, identification and quantification using the VS38 panel were easier.
Conclusions
VS38 is a viable alternative to bright CD38 to identify plasma cells and particularly helpful in myeloma cases with dim CD38 and after daratumumab. Daratumumab interference with CD38 identification persists 4 to 6 months after the last exposure.</description><identifier>ISSN: 0002-9173</identifier><identifier>EISSN: 1943-7722</identifier><identifier>DOI: 10.1093/ajcp/aqz153</identifier><identifier>PMID: 31679012</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>ADP-ribosyl Cyclase 1 - analysis ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal - analysis ; Antibodies, Monoclonal - therapeutic use ; CD38 antigen ; Diagnosis ; Drug therapy ; Female ; Flow Cytometry ; Glycoproteins ; Health aspects ; Humans ; Immunodiagnosis ; Immunotherapy ; Killer Cells, Natural - chemistry ; Male ; Methods ; Middle Aged ; Monoclonal antibodies ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - immunology ; Multiple Myeloma - pathology ; Myeloma ; Natural killer cells ; Patient outcomes ; Plasma ; Plasma cells ; Plasma Cells - chemistry ; Targeted cancer therapy ; Time Factors</subject><ispartof>American journal of clinical pathology, 2020-02, Vol.153 (2), p.221-228</ispartof><rights>American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2019</rights><rights>American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><rights>COPYRIGHT 2020 Oxford University Press</rights><rights>American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-bb2421a954cbcdf884265d8d419cbf4486f8a1d4969020bfb8dfaf8e0bfe0fd93</citedby><cites>FETCH-LOGICAL-c452t-bb2421a954cbcdf884265d8d419cbf4486f8a1d4969020bfb8dfaf8e0bfe0fd93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31679012$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Courville, Elizabeth L</creatorcontrib><creatorcontrib>Yohe, Sophia</creatorcontrib><creatorcontrib>Shivers, Paula</creatorcontrib><creatorcontrib>Linden, Michael A</creatorcontrib><title>VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months</title><title>American journal of clinical pathology</title><addtitle>Am J Clin Pathol</addtitle><description>Abstract
Objectives
We report our institutional experience using VS38 to evaluate plasma cells by flow cytometry.
Methods
Flow cytometry data were reanalyzed to compare plasma cell percentages between the standard panel and VS38 panel. Natural killer (NK) and plasma cell CD38 median fluorescence intensity (MFI) values were calculated.
Results
Our cohort included 63 specimens from 38 patients. Twenty-six had received daratumumab (monoclonal anti-CD38 therapy) between less than 1 month and 17 months prior. For NK and plasma cells, CD38 MFI values were suppressed for 0 to 4 months and started to increase 4 to 6 months after last exposure. There was no significant difference in clonal plasma cell percentage calculated by the VS38 and standard panels; however, identification and quantification using the VS38 panel were easier.
Conclusions
VS38 is a viable alternative to bright CD38 to identify plasma cells and particularly helpful in myeloma cases with dim CD38 and after daratumumab. Daratumumab interference with CD38 identification persists 4 to 6 months after the last exposure.</description><subject>ADP-ribosyl Cyclase 1 - analysis</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal - analysis</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>CD38 antigen</subject><subject>Diagnosis</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Flow Cytometry</subject><subject>Glycoproteins</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunodiagnosis</subject><subject>Immunotherapy</subject><subject>Killer Cells, Natural - chemistry</subject><subject>Male</subject><subject>Methods</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - immunology</subject><subject>Multiple Myeloma - pathology</subject><subject>Myeloma</subject><subject>Natural killer cells</subject><subject>Patient outcomes</subject><subject>Plasma</subject><subject>Plasma cells</subject><subject>Plasma Cells - chemistry</subject><subject>Targeted cancer therapy</subject><subject>Time Factors</subject><issn>0002-9173</issn><issn>1943-7722</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9ktFqFDEUhgdR7Fq98l4CQhF02iSTySSXZbfVhRYFq70MmUzSzTKTTJMMur6L72rWqRVFJBfJCd_5OCF_UTxH8BhBXp3IrRpP5O03VFcPigXipCqbBuOHxQJCiEuOmuqgeBLjFkKEGSSPi4MK0YbnalF8__yxYmDdaZessTqCy53u_SDBUvd9BNc2bcDKDmC5ytjZ1zHoGK13QLoOfOhlvCfPfd_7L9bdgJUMMk3DNMgWXG10kOPuDbjeWLUBa5d0MDpLZvNP60onrdJeanwABCQPKLj0Lm3i0-KRkX3Uz-72w-LT-dnV8l158f7tenl6USpS41S2LSYYSV4T1arOMEYwrTvWEcRVawhh1DCJOsIphxi2pmWdkYbpfNTQdLw6LF7N3jH420nHJAYbVX6XdNpPUeAKIY5hQ6uMvvwL3fopuDydyEPUNaWQ8t_Ujey1sM74FKTaS8UpJTVkEFKYqeN_UHl1erDKO21svv-j4fXcoIKPMWgjxmAHGXYCQbEPg9iHQcxhyPSLu1GndtDdPfvr9zNwNAN-Gv9r-gFy-bt8</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Courville, Elizabeth L</creator><creator>Yohe, Sophia</creator><creator>Shivers, Paula</creator><creator>Linden, Michael A</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20200201</creationdate><title>VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months</title><author>Courville, Elizabeth L ; Yohe, Sophia ; Shivers, Paula ; Linden, Michael A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-bb2421a954cbcdf884265d8d419cbf4486f8a1d4969020bfb8dfaf8e0bfe0fd93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>ADP-ribosyl Cyclase 1 - analysis</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal - analysis</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>CD38 antigen</topic><topic>Diagnosis</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Flow Cytometry</topic><topic>Glycoproteins</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunodiagnosis</topic><topic>Immunotherapy</topic><topic>Killer Cells, Natural - chemistry</topic><topic>Male</topic><topic>Methods</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - immunology</topic><topic>Multiple Myeloma - pathology</topic><topic>Myeloma</topic><topic>Natural killer cells</topic><topic>Patient outcomes</topic><topic>Plasma</topic><topic>Plasma cells</topic><topic>Plasma Cells - chemistry</topic><topic>Targeted cancer therapy</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Courville, Elizabeth L</creatorcontrib><creatorcontrib>Yohe, Sophia</creatorcontrib><creatorcontrib>Shivers, Paula</creatorcontrib><creatorcontrib>Linden, Michael A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Courville, Elizabeth L</au><au>Yohe, Sophia</au><au>Shivers, Paula</au><au>Linden, Michael A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months</atitle><jtitle>American journal of clinical pathology</jtitle><addtitle>Am J Clin Pathol</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>153</volume><issue>2</issue><spage>221</spage><epage>228</epage><pages>221-228</pages><issn>0002-9173</issn><eissn>1943-7722</eissn><abstract>Abstract
Objectives
We report our institutional experience using VS38 to evaluate plasma cells by flow cytometry.
Methods
Flow cytometry data were reanalyzed to compare plasma cell percentages between the standard panel and VS38 panel. Natural killer (NK) and plasma cell CD38 median fluorescence intensity (MFI) values were calculated.
Results
Our cohort included 63 specimens from 38 patients. Twenty-six had received daratumumab (monoclonal anti-CD38 therapy) between less than 1 month and 17 months prior. For NK and plasma cells, CD38 MFI values were suppressed for 0 to 4 months and started to increase 4 to 6 months after last exposure. There was no significant difference in clonal plasma cell percentage calculated by the VS38 and standard panels; however, identification and quantification using the VS38 panel were easier.
Conclusions
VS38 is a viable alternative to bright CD38 to identify plasma cells and particularly helpful in myeloma cases with dim CD38 and after daratumumab. Daratumumab interference with CD38 identification persists 4 to 6 months after the last exposure.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>31679012</pmid><doi>10.1093/ajcp/aqz153</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9173 |
| ispartof | American journal of clinical pathology, 2020-02, Vol.153 (2), p.221-228 |
| issn | 0002-9173 1943-7722 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2311920763 |
| source | Oxford Journals Online |
| subjects | ADP-ribosyl Cyclase 1 - analysis Adult Aged Aged, 80 and over Antibodies, Monoclonal - analysis Antibodies, Monoclonal - therapeutic use CD38 antigen Diagnosis Drug therapy Female Flow Cytometry Glycoproteins Health aspects Humans Immunodiagnosis Immunotherapy Killer Cells, Natural - chemistry Male Methods Middle Aged Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - immunology Multiple Myeloma - pathology Myeloma Natural killer cells Patient outcomes Plasma Plasma cells Plasma Cells - chemistry Targeted cancer therapy Time Factors |
| title | VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T14%3A18%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=VS38%20Identifies%20Myeloma%20Cells%20With%20Dim%20CD38%20Expression%20and%20Plasma%20Cells%20Following%20Daratumumab%20Therapy,%20Which%20Interferes%20With%20CD38%20Detection%20for%204%20to%206%20Months&rft.jtitle=American%20journal%20of%20clinical%20pathology&rft.au=Courville,%20Elizabeth%20L&rft.date=2020-02-01&rft.volume=153&rft.issue=2&rft.spage=221&rft.epage=228&rft.pages=221-228&rft.issn=0002-9173&rft.eissn=1943-7722&rft_id=info:doi/10.1093/ajcp/aqz153&rft_dat=%3Cgale_proqu%3EA645080060%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c452t-bb2421a954cbcdf884265d8d419cbf4486f8a1d4969020bfb8dfaf8e0bfe0fd93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2425566069&rft_id=info:pmid/31679012&rft_galeid=A645080060&rft_oup_id=10.1093/ajcp/aqz153&rfr_iscdi=true |